Efgartigimod (VYVGART/VYVGART Hytrulo) is a prescription medicine for the treatment of gMG in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive). It is designed as a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn).
Despite numerous adverse effects, including osteoporosis, weight gain, diabetes, and increased susceptibility to infections, oral corticosteroids (OCS) are frequently employed in the management of myasthenia gravis symptoms by suppressing the immune response. Therefore, reducing or tapering OCS usage is crucial to mitigate these risks wh...
